| ²é¿´: 595 | »Ø¸´: 6 | ||
¹·æ¤Ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖúһϻشðÏÂÎÊÌâ
|
| Why do manufactures of sustained release drug product attempt to design this dosage form to have a zero-order rate of systemic drug absorption? |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøT0PÎÄÕ£¬ÎÒ:8.O55.1.O.54,¿ÆÄ¿È«,¿ÉÊ®¼±
ÒѾÓÐ9È˻ظ´
ÊÛSCIÎÄÕ£¬ÎÒ:8O5.5.1.O.54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøT0PÎÄÕ£¬ÎÒ:8.O.55.1.O54,¿ÆÄ¿È«,¿ÉÙ¤¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøT0PÎÄÕ£¬ÎÒ:8.O.55.1.O54,¿ÆÄ¿È«,¿ÉÙ¤¼±
ÒѾÓÐ5È˻ظ´
ÊÛÒ»ÇøSCIÎÄÕÂT0P£¬ÎÒ:8O.551.O54,¿ÆÄ¿È«,¿ÉÊ®¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.55.1.O.54,¿ÆÄ¿ÆëÈ«,¿ÉÙ¤¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÎÄÕ£¬ÎÒ:8O5.5.1.O.54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.55.1.O.54,¿ÆÄ¿ÆëÈ«,¿ÉÙ¤¼±
ÒѾÓÐ9È˻ظ´
¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶ÓÌÖÂÛ
ÒѾÓÐ15È˻ظ´
ÖÐÇà»ùÁËÒª·¢ÅóÓÑȦÂð£¿
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÖúÁ½¸öBÀà´íÎ󣬻شðÉó¸åÈËÌá³öµÄÎÊÌâ
ÒѾÓÐ4È˻ظ´
ÈËÎĵØÀíѧÎÊÌâÇó½â´ð
ÒѾÓÐ4È˻ظ´
ÇóÖú£¬Ð¡ÐÞÈçºÎ»Ø´ðreviewerµÄ¼¬ÊÖÎÊÌ⣿
ÒѾÓÐ3È˻ظ´
СµÜÇóÖú¹ØÓÚÇ⻯¸Æ¸ÉÔïDMFµÄÎÊÌâ--¼±¼±¼±¼±--´ó¼Ò°ïæ½â´ðһϰɣ¡
ÒѾÓÐ8È˻ظ´
ÇóÖúÔõô»Ø´ðÉó¸åÈ˵ÄÎÊÌâ
ÒѾÓÐ14È˻ظ´
ÎÊÒ»¸öÓëÒ©³§ÓйصÄÎÊÌ⣬Çó½â´ð¡¢¡¢¡¢
ÒѾÓÐ9È˻ظ´
ÓйؽÍĸ¾ú·¢½ÍµÄһЩÎÊÌ⣬´ó¼Ò¿ÉÒÔ½»Á÷Ò»ÏÂ
ÒѾÓÐ8È˻ظ´
ÐÂÈËͶ¸åÇóÖúÒ»¸öÎÊÌâ¸ÃÔõô»Ø´ð£¨ÔÚÏߵȣ©
ÒѾÓÐ8È˻ظ´
±¾È˲éÔÄÎÄÏ×£¬Óöµ½Ò»¸öÎÊÌ⣬Çë½ÌÄÄλ¸øÎÒ½â´ð¹þ£¬ÔÚϽ«²»Ê¤¸Ð¼¤£¡
ÒѾÓÐ18È˻ظ´
²»ÖªµÀÔõô»Ø´ðÉó¸åÈ˵ÄÎÊÌ⣬ÇóÖú´ó¼Ò,(¹ØÓÚ·Ö×ÓɸMCM-41µÄ£©
ÒѾÓÐ10È˻ظ´
ÇóÖúÁ½µÀÌâµÄ½â´ð
ÒѾÓÐ9È˻ظ´
¡¾ÇóÖú¡¿Çó½â´ð
ÒѾÓÐ13È˻ظ´
¡¾ÇóÖú¡¿ÇëÁªºÏÅàÑøµÄͬѧ»òÓоÑéµÄͬѧ°ïÖú»Ø´ð---·¢±íÎÄÕÂÊðÃûÎÊÌâ
ÒѾÓÐ19È˻ظ´
¡¾ÇóÖú¡¿¼¯ÁеÄÉÏϼ«ÏÞµÄÈý¸öÎÊÌ⣿Çë´óϺ½â´ð
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú¡¿µç×ÓÃܶÈÎÊÌâ-ÈçºÎ»Ø´ðÆÀÉóÈ˵ÄÎÊÌ⣿¼±°¡
ÒѾÓÐ10È˻ظ´
¡¾ÇóÖú¡¿¼±£¬°ïæ·ÖÎöһϵ¼Ê¦µÄ»Ø´ð
ÒѾÓÐ15È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚXRD·ÛÄ©ÑÜÉäÖÆÑùϸ½ÚµÄÎÊÌ⡾¸÷ÖֻشðÈÃÎÒÃÔãÁË£¬ÇóȨÍþ¡¿
ÒѾÓÐ20È˻ظ´
¡¾ÇóÖú¡¿Çó½â´ðÑõ»¯î÷µÄ¹â´ß»¯ÎÊÌâ
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú¡¿Çó¡¶°ëµ¼ÌåÎïÀíѧ¡·£¨Áõ¶÷¿Æ£¬7°æ£©¿ÎºóϰÌâ½â´ð
ÒѾÓÐ15È˻ظ´
netscaner
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 237 (´óѧÉú)
- ½ð±Ò: 8270.5
- É¢½ð: 20
- ºì»¨: 16
- Ìû×Ó: 631
- ÔÚÏß: 87.8Сʱ
- ³æºÅ: 242727
- ×¢²á: 2006-04-11
- רҵ: Ö²Îï×ÊԴѧ

2Â¥2012-10-06 09:05:05
¹·æ¤
гæ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 70.9
- É¢½ð: 6
- Ìû×Ó: 149
- ÔÚÏß: 58.4Сʱ
- ³æºÅ: 1984194
- ×¢²á: 2012-09-08
- רҵ: ÊýÀíͳ¼Æ
3Â¥2012-10-06 15:48:19
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
4Â¥2012-10-06 17:10:41
netscaner
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 237 (´óѧÉú)
- ½ð±Ò: 8270.5
- É¢½ð: 20
- ºì»¨: 16
- Ìû×Ó: 631
- ÔÚÏß: 87.8Сʱ
- ³æºÅ: 242727
- ×¢²á: 2006-04-11
- רҵ: Ö²Îï×ÊԴѧ

5Â¥2012-10-07 06:05:02
¹·æ¤
гæ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 70.9
- É¢½ð: 6
- Ìû×Ó: 149
- ÔÚÏß: 58.4Сʱ
- ³æºÅ: 1984194
- ×¢²á: 2012-09-08
- רҵ: ÊýÀíͳ¼Æ
|
1. An industrial pharmacist would like to design a controlled release drug product to be given every 12 hour. The active drug ingredient has an apparent volume of distribution of 10 L, an elimination half-life of 3.5 hours, and a desired therapeutic plasma drug concentration of 20 mg/ml. Calculation the zero-order release rate of the sustained-release drug product and the total amount of drug needed, assuming no initializing dose is required. 2. Why do manufactures of sustained release drug product attempt to design this dosage form to have a zero-order rate of systemic drug absorption? Äú¾õµÃÕâÁ½µÀÌâÓйØÁªÊÇÂð£¿ÄÇÂé·³Äú°ïÎÒ½â´ðһϺÃÂð£¿Ð»Ð»À² |
6Â¥2012-10-07 13:49:37
¹·æ¤
гæ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 70.9
- É¢½ð: 6
- Ìû×Ó: 149
- ÔÚÏß: 58.4Сʱ
- ³æºÅ: 1984194
- ×¢²á: 2012-09-08
- רҵ: ÊýÀíͳ¼Æ
7Â¥2012-10-07 13:50:20









»Ø¸´´ËÂ¥
10